Crotamiton

Summary

Crotamiton (CHEMBL6067975) is an approved unknown targeting TRPV4; indicated across 1 condition including scabies.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Targets: 1 (TRPV4)
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067975
Name	Crotamiton
Type	Unknown
Max phase	4

Also known as: Crotamiton, Crotan, Eurax, N-ethyl-o-crotonotoluidide, N-ethylcrotono-o-toluidide, NSC-758951, CROTAMITON

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPV4	TRPV4	Inhibition		0.6%	Q9HBA0

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPV4.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPV4
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	1	TRPV4

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
response to hypoxia	1
diet induced thermogenesis	1
calcium ion transport	1
intracellular calcium ion homeostasis	1
cell volume homeostasis	1
actin filament organization	1
cell-cell junction assembly	1
positive regulation of cytosolic calcium ion concentration	1
osmosensory signaling pathway	1
response to mechanical stimulus	1
positive regulation of macrophage chemotaxis	1
negative regulation of neuron projection development	1
actin cytoskeleton organization	1
vasopressin secretion	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
scabies	4	MONDO:0004525

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
CANNABINOL	ChEMBL	Phase 3	TRPV4
CANNABIDIVARIN	ChEMBL	Phase 2	TRPV4
CANNABIGEROL	ChEMBL	Phase 2	TRPV4
GSK2798745	ChEMBL	Phase 2	TRPV4
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV4